Advanced Filters
noise

La Jolla, California Clinical Trials

A listing of La Jolla, California clinical trials actively recruiting patient volunteers.

Found 718 clinical trials
J Juan Molina, MD

Neurophysiologic Biomarkers for Cognitive Rehabilitation

Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizophrenia patients may experience modest clinical and cognitive benefits from cognitive remediation. To enhance …

18 - 75 years of age All Phase N/A
S Site Public Contact

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody …

18 years of age All Phase 2
M Monica Guma, M.D, PHD

Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites. The current study will determine whether or not the addition of anti-inflammatory diet improves the clinical outcomes in participants with rheumatoid arthritis, and …

18 years of age All Phase N/A

The Tether™ - Vertebral Body Tethering System Post Approval Study

This study is an opportunity to provide continued reasonable assurance of the safety and probable benefit of The Tether HUD. The study will collect long term safety and efficacy information from patients who have had their idiopathic scoliosis treated via anterior vertebral body tethering (AVBT) with The Tether.

years of age All Phase N/A
M Mitchell Humphreys, MD

Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy

A prospective, multi-center, non-randomized trial to demonstrate safety and device performance of the ADVA-Tec Uriprene® Degradable Temporary Ureteral Stent.

21 - 80 years of age All Phase N/A
D Dr Nishitha Pillai

A Study to Assess Growth in Children With Idiopathic Short Stature

Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.

2 - 16 years of age All Phase N/A
K Katherine Spaulding

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to …

18 - 75 years of age All Phase 4
S Sarah Topol, RN

Molecular Autopsy Study

This study seeks to incorporate genetic testing into the postmortem examination of cases of sudden unexplained death.

- 45 years of age All Phase N/A
O Oleg G Khatsenko

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome

14 years of age All Phase 2/3
K Kiley Borchard

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed …

18 years of age All Phase 1

Simplify language using AI